
Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (3): 231-236.doi: 10.11958/20230719
• Cell and Molecular Biology • Previous Articles Next Articles
MAN Jun1(
), GAO Yanyan1, SONG Longfei2, GAO Fusheng1,△(
)
Received:2023-05-19
Revised:2023-08-12
Published:2024-03-15
Online:2024-03-13
Contact:
△E-mail: MAN Jun, GAO Yanyan, SONG Longfei, GAO Fusheng. The effect of lncRNA FEZF1-AS1 targeting regulation of miR-200c-3p on biological behaviors of human lung fibroblasts[J]. Tianjin Medical Journal, 2024, 52(3): 231-236.
CLC Number:
| 基因名称 | 引物序列(5'→3') | 产物大小/bp |
|---|---|---|
| LncRNA FEZF1-AS1 | 上游:TTAGGAGGCTTGTTCTGTGT | 239 |
| 下游:GCGCAGGTACTTAAGAAAGA | ||
| miR-200c-3p | 上游:UAAUACUGCCGGGUAAUGAUGGA | 70 |
| 下游:UCCAUCAUUACCCGGCAGUAUUA | ||
| GAPDH | 上游:GCCTTCCGTGTCCCCACTGC | 216 |
| 下游:GGCTGGTGGTCCAGGGGTCT | ||
| U6 | 上游:CTCGCTTCGGCAGCACA | 65 |
| 下游:AACGCTTCACGAATTTGCGT |
Tab.1 Primer sequence
| 基因名称 | 引物序列(5'→3') | 产物大小/bp |
|---|---|---|
| LncRNA FEZF1-AS1 | 上游:TTAGGAGGCTTGTTCTGTGT | 239 |
| 下游:GCGCAGGTACTTAAGAAAGA | ||
| miR-200c-3p | 上游:UAAUACUGCCGGGUAAUGAUGGA | 70 |
| 下游:UCCAUCAUUACCCGGCAGUAUUA | ||
| GAPDH | 上游:GCCTTCCGTGTCCCCACTGC | 216 |
| 下游:GGCTGGTGGTCCAGGGGTCT | ||
| U6 | 上游:CTCGCTTCGGCAGCACA | 65 |
| 下游:AACGCTTCACGAATTTGCGT |
| 组别 | α-SMA | Collagen Ⅰ | Vimentin |
|---|---|---|---|
| Blank组 | 0.68±0.02 | 0.37±0.05 | 0.66±0.06 |
| HLF+TGF-β1组 | 0.90±0.02 | 0.68±0.05 | 0.98±0.04 |
| t | 7.621* | 7.431* | 4.583* |
Tab.2 Comparison of α-SMA, Collagen Ⅰ and Vimentin protein expressions between two groups of cells
| 组别 | α-SMA | Collagen Ⅰ | Vimentin |
|---|---|---|---|
| Blank组 | 0.68±0.02 | 0.37±0.05 | 0.66±0.06 |
| HLF+TGF-β1组 | 0.90±0.02 | 0.68±0.05 | 0.98±0.04 |
| t | 7.621* | 7.431* | 4.583* |
| 组别 | 0 h | 24 h | 48 h | F |
|---|---|---|---|---|
| Blank组 | 0.49±0.00 | 0.65±0.01A | 1.08±0.02AB | 640.000* |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.48±0.01 | 1.08±0.03aA | 1.87±0.03aAB | 641.500* |
| TGF-β1+Si LncRNA FEZF1-AS1组 | 0.47±0.02 | 0.84±0.01abA | 1.53±0.07abAB | 185.300* |
| F | 0.719 | 108.400* | 79.310* |
Tab.3 Comparison of cell proliferation between three groups
| 组别 | 0 h | 24 h | 48 h | F |
|---|---|---|---|---|
| Blank组 | 0.49±0.00 | 0.65±0.01A | 1.08±0.02AB | 640.000* |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.48±0.01 | 1.08±0.03aA | 1.87±0.03aAB | 641.500* |
| TGF-β1+Si LncRNA FEZF1-AS1组 | 0.47±0.02 | 0.84±0.01abA | 1.53±0.07abAB | 185.300* |
| F | 0.719 | 108.400* | 79.310* |
| 组别 | 划痕愈合率/% | 侵袭细胞数/(个/视野) |
|---|---|---|
| Blank组 | 61.98±1.56 | 236.00±2.08 |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 89.16±0.78a | 413.30±16.23a |
| TGF-β1+Si LncRNA FEZF1-AS1组 | 79.74±0.68ab | 329.30±25.22ab |
| F | 162.500* | 26.120* |
Tab.4 Comparison of cell scratch healing rate and invasion number between three groups
| 组别 | 划痕愈合率/% | 侵袭细胞数/(个/视野) |
|---|---|---|
| Blank组 | 61.98±1.56 | 236.00±2.08 |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 89.16±0.78a | 413.30±16.23a |
| TGF-β1+Si LncRNA FEZF1-AS1组 | 79.74±0.68ab | 329.30±25.22ab |
| F | 162.500* | 26.120* |
| 组别 | α-SMA | CollagenⅠ | Vimentin |
|---|---|---|---|
| Blank组 | 0.57±0.01 | 0.32±0.02 | 0.33±0.01 |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.85±0.02a | 0.84±0.01a | 0.92±0.01a |
| TGF-β1+Si LncRNA FEZF1-AS1 组 | 0.70±0.02ab | 0.67±0.03ab | 0.67±0.01ab |
| F | 65.610* | 129.100* | 1170.000* |
Tab.5 Expressions of α-SMA, CollagenⅠ and Vimentin in each group
| 组别 | α-SMA | CollagenⅠ | Vimentin |
|---|---|---|---|
| Blank组 | 0.57±0.01 | 0.32±0.02 | 0.33±0.01 |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.85±0.02a | 0.84±0.01a | 0.92±0.01a |
| TGF-β1+Si LncRNA FEZF1-AS1 组 | 0.70±0.02ab | 0.67±0.03ab | 0.67±0.01ab |
| F | 65.610* | 129.100* | 1170.000* |
| 组别 | LncRNA FEZF1-AS1 | miR-200c-3p |
|---|---|---|
| Blank组 | 1.28±0.11 | 1.05±0.02 |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 7.53±0.14a | 0.15±0.01a |
| TGF-β1+Si LncRNA FEZF1-AS1组 | 2.62±0.04ab | 0.45±0.00ab |
| F | 952.100* | 1 065.000* |
Tab.6 Expressions of LncRNA FEZF1-AS1 and miR-200c-3p in each group
| 组别 | LncRNA FEZF1-AS1 | miR-200c-3p |
|---|---|---|
| Blank组 | 1.28±0.11 | 1.05±0.02 |
| TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 7.53±0.14a | 0.15±0.01a |
| TGF-β1+Si LncRNA FEZF1-AS1组 | 2.62±0.04ab | 0.45±0.00ab |
| F | 952.100* | 1 065.000* |
| [1] | KATZEN J, BEERS M F. Contributions of alveolar epithelial cell quality control to pulmonary fibrosis[J]. J Clin Invest, 2020, 130(10):5088-5099. doi:10.1172/JCI139519. |
| [2] | MA H B, WU X Y, LI Y, et al. Research progress in the molecular mechanisms,therapeutic targets,and drug development of idiopathic pulmonary fibrosis[J]. Front Pharmacol, 2022, 13:963054. doi:10.3389/fphar.2022.963054. |
| [3] | COX I A, OTAHAL P, DE GRAAFF B, et al. Incidence,prevalence and mortality of idiopathic pulmonary fibrosis in Australia[J]. Respirology, 2022, 27(3):209-216. doi:10.1111/resp.14194. |
| [4] | VANCHERI C, KREUTER M, RICHELDI L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. results of the INJOURNEY trial[J]. Am J Respir Crit Care Med, 2018, 197(3):356-363. doi:10.1164/rccm.201706-1301OC. |
| [5] | BRIDGES M C, DAULAGALA A C, KOURTIDIS A. LNCcation:lncRNA localization and function[J]. J Cell Biol, 2021, 220(2):e202009045. doi:10.1083/jcb.202009045. |
| [6] | ZHANG T, YU S, ZHAO S. LncRNA FEZF1-AS1 promotes colorectal cancer progression through regulating the miR-363-3p/PRRX1 pathway[J]. Adv Clin Exp Med, 2021, 30(8):839-848. doi:10.17219/acem/135693. |
| [7] | PONTEMEZZO E, FOGLIO E, VERNUCCI E, et al. miR-200c-3p regulates epitelial-to-mesenchymal transition in epicardial mesothelial cells by targeting epicardial follistatin-related protein 1[J]. Int J Mol Sci, 2021, 22(9):4971. doi:10.3390/ijms22094971. |
| [8] | WANG Y, LU K, LI W, et al. MiR-200c-3p aggravates gastric cell carcinoma via KLF6[J]. Genes Genomics, 2021, 43(11):1307-1316. doi:10.1007/s13258-021-01160-6. |
| [9] | KURUNDKAR A R, KURUNDKAR D, RANGARAJAN S, et al. The matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury[J]. FASEB J, 2016, 30(6):2135-2150. doi:10.1096/fj.201500173. |
| [10] | HERMAN A B, TSITSIPATIS D, GOROSPE M. Integrated lncRNA function upon genomic and epigenomic regulation[J]. Mol Cell, 2022, 82(12):2252-2266. doi:10.1016/j.molcel.2022.05.027. |
| [11] | WANG H, WU Y, WANG Z, et al. The LncRNA FEZF1-AS1 promotes tumor proliferation in colon cancer by regulating the mitochondrial protein PCK2[J]. Oncol Res, 2022, 29(3):201-215. doi:10.32604/or.2022.03553. |
| [12] | LIANG M, LI Y, DAI T, et al. lncRNA FEZF1-AS1 regulates biological behaviors of cervical cancer by targeting miRNA-1254[J]. Food Sci Nutr, 2021, 9(9):4722-4737. doi:10.1002/fsn3.2315. |
| [13] | HE R, ZHANG F H, SHEN N. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC)[J]. Biomed Pharmacother, 2017, 95:331-338. doi:10.1016/j.biopha.2017.08.057. |
| [14] | WANG Z H, WANG J H, WANG K Q, et al. LncRNA FEZF1-AS1 promoted chemoresistance,autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis in prostate cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(16):8250. doi:10.26355/eurrev_202008_22591. |
| [15] | WANG Y D, SUN X J, YIN J J, et al. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma[J]. Biomed Pharmacother, 2018, 106:134-141. doi:10.1016/j.biopha.2018.05.116. |
| [16] | MOIMAS S, SALTON F, KOSMIDER B, et al. miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation[J]. ERJ Open Res, 2019, 5(4):00138-2019. doi:10.1183/23120541.00138-2019. |
| [17] | LIN S, ZHANG R, XU L, et al. LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1[J]. Cell Death Dis, 2020, 11(8):706. doi:10.1038/s41419-020-02889-w. |
| [1] | XU Shuguang, GUAN Shuhong, ZHANG Yunfeng. Application effect of cluster management in peri-discharge period of patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Tianjin Medical Journal, 2025, 53(11): 1170-1175. |
| [2] | LIU Xin, GU Jing, YANG Jie, CHEN Xinping, CAI Chuanfeng, ZHANG Xiumei. The influencing factors of readmission within 90 days for weak patients with chronic obstructive pulmonary disease and construction of an early warning model [J]. Tianjin Medical Journal, 2025, 53(10): 1061-1065. |
| [3] | CHEN Miaomiao, ZHANG Yazheng, ZHAO Fang, YANG Liheng, JIAO Lina, ZHAO Xiaoyun. Multi-omics analysis of the causal relationship and mediation mechanisms between obstructive sleep apnea and atrial fibrillation [J]. Tianjin Medical Journal, 2025, 53(9): 946-951. |
| [4] | ZHANG Xiaoqing, ZHAO Huixia, CAO Ehong, ZHANG Lianxia, GONG Xiujuan. Application value of PIV, HCAR and PCT/PLT in pulmonary infection in elderly patients with COPD [J]. Tianjin Medical Journal, 2025, 53(2): 170-175. |
| [5] | YU Zhihong, WANG Xiaoqin. Effects of imperatorin derivatives on the activity and drug resistance protein of alveolar type Ⅱ epithelial cells in COPD [J]. Tianjin Medical Journal, 2024, 52(11): 1127-1130. |
| [6] | LI Dongsheng, QIN Yirong, QIAO Man, CHI Hang, CUI Qingmin, LI Xiaoqiu. Clinical effects of Qingke Pingchuan Granule on acute exacerbation of COPD [J]. Tianjin Medical Journal, 2024, 52(8): 854-857. |
| [7] | LI Xin, LI Xue, WANG An. Effects of chrysotile on expression of Wnt5a, p16 and p21 in endothelial cells [J]. Tianjin Medical Journal, 2024, 52(7): 679-682. |
| [8] | FENG Liting, LI Li, XIE Xin, WANG Xing. Analysis of influencing factors of chronic obstructive pulmonary disease in permanent residents in some area of Tianjin [J]. Tianjin Medical Journal, 2024, 52(4): 427-431. |
| [9] | LUO Cheng, ZHANG Ning, PENG Yanru, LI Shu, GUO Yali, WANG Yuguang. Analysis of the clinical characteristics and influencing factors of fatigue symptoms in patients with interstitial lung disease [J]. Tianjin Medical Journal, 2023, 51(11): 1237-1241. |
| [10] | XU Nongyu, ZHONG Jiangshan, LI Duo. Protective effect and mechanism of inosine on acute lung injury induced by lipopolysaccharide in rats [J]. Tianjin Medical Journal, 2023, 51(10): 1071-1075. |
| [11] | XIONG Gaocai, YANG Yuanfeng, LI Jiasong, LIU Tingqian, HE Bingbing, LIU Zhuoling. Early diagnostic value of serum miR-134-5p and miR-320a combined with pulmonary function index in coal worker pneumoconiosis patients [J]. Tianjin Medical Journal, 2023, 51(8): 860-863. |
| [12] | SUN Liyan, LIU Zeru, SU Yongsheng, AI Hongliang. Effect of asperuloside on pyroptosis of lung tissue in septic rats by regulating NLRP3/Caspase-1/GSDMD signaling pathway [J]. Tianjin Medical Journal, 2023, 51(6): 607-612. |
| [13] | HUANG Chengjun, XU Yu, MI Le, WANG Xiujun, LIU Zhenfeng, WANG Hongman. Research progress of autophagy in acute respiratory distress syndrome [J]. Tianjin Medical Journal, 2023, 51(6): 668-672. |
| [14] | HAN Jiao, WANG Huabing, XU Lingwen, DONG Fang. The role of γ-secretase inhibitor in pulmonary fibrosis epithelial-mesenchymal transition [J]. Tianjin Medical Journal, 2022, 50(9): 917-920. |
| [15] | WANG Le, CHEN Xing, LIANG Maoli, ZHANG Jing, WANG Yan, CHEN Baoyuan, CAO Jie. Analysis of influencing factors and predictive indicators of obstructive sleep apnea combined with obesity-related sleep hypoventilation [J]. Tianjin Medical Journal, 2022, 50(9): 953-958. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||